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Cardiovascular diseases and cancers are the leading causes of morbidity and mortality
in the world. MicroRNAs (miRNAs) are short non-coding RNAs that primarily repress
target mRNAs. Here, miR-24, miR-125b, miR-195, and miR-214 were selected as
representative cardio-miRs that are upregulated in human heart failure. To bridge the
gap between miRNA studies in cardiology and oncology, the targets and functions of
these miRNAs in cardiovascular diseases and cancers will be reviewed. ACVR1B, BCL2,
BIM, eNOS, FGFR3, JPH2, MEN1, MYC, p16, and ST7L are miR-24 targets that have
been experimentally validated in human cells. ARID3B, BAK1, BCL2, BMPR1B, ERBB2,
FGFR2, IL6R, MUC1, SITR7, Smoothened, STAT3, TET2, and TP53 are representative
miR-125b targets. ACVR2A, BCL2, CCND1, E2F3, GLUT3, MYB, RAF1, VEGF, WEE1,
and WNT7A are representative miR-195 targets. BCL2L2, ß-catenin, BIM, CADM1, EZH2,
FGFR1, NRAS, PTEN, TP53, and TWIST1 are representative miR-214 targets. miR-125b
is a good cardio-miR that protects cardiomyocytes; miR-195 is a bad cardio-miR that
elicits cardiomyopathy and heart failure; miR-24 and miR-214 are bi-functional cardio-
miRs. By contrast, miR-24, miR-125b, miR-195, and miR-214 function as oncogenic or
tumor suppressor miRNAs in a cancer (sub)type-dependent manner. Circulating miR-24
is elevated in diabetes, breast cancer and lung cancer. Circulating miR-195 is elevated
in acute myocardial infarction, breast cancer, prostate cancer and colorectal adenoma.
Circulating miR-125b and miR-214 are elevated in some cancers. Cardio-miRs and
onco-miRs bear some similarities in functions and circulation profiles. miRNAs regulate
WNT, FGF, Hedgehog and other signaling cascades that are involved in orchestration of
embryogenesis and homeostasis as well as pathogenesis of human diseases. Because
circulating miRNA profiles are modulated by genetic and environmental factors and are
dysregulated by genetic and epigenetic alterations in somatic cells, circulating miRNA
association studies (CMASs) within several thousands of cases each for common
non-cancerous diseases and major cancers are necessary for miRNA-based diagnostics.
Keywords: Alzheimer’s disease, early diagnosis, gastric cancer, hypertension, pancreatic cancer, personalize
medicine, rheumatoid arthritis, stem cells
INTRODUCTION
MicroRNAs (miRNAs) are short non-coding RNAs that primar-
ily repress protein expression from target mRNAs with imperfect
or perfect complementarity through mRNA degradation and
translational inhibition or mRNA cleavage, respectively (Kasinski
and Slack, 2011; van Rooij and Olson, 2012). For example,
miR-15, miR-16, miR-20a, and miR-20b are anti-angiogenic
miRNAs that repress VEGFA (VEGF) (Wang and Olson, 2009;
Katoh, 2013b). miR-200 family members inhibit epithelial-to-
mesenchymal transition (EMT) and self-renewal of stem cells
through repression of ZEB1/2 and BMI1, respectively (Katoh and
Katoh, 2008; Oishi et al., 2012; Feng et al., 2014). miRNAs regu-
late a variety of cellular processes, such as stemness, proliferation,
senescence, apoptosis, inflammatory cytokine production, EMT,
metastasis and drug resistance.
Cardiovascular diseases and cancers are the leading causes of
morbidity and mortality in the world (Lozano et al., 2012). miR-
NAs involved in heart diseases (Divakaran and Mann, 2008),
vascular diseases (Wang and Olson, 2009) and cancers (Croce,
2009) are designated cardio-miRs, angio-miRs, and onco-miRs,
respectively, and the same miRNA can function as a cardio-miR,
angio-miR or onco-miR in a context-dependent manner. Among
32,233 miRNA manuscripts in the PubMed database, 3334 and
15,740 manuscripts were extracted by using cardiovascular and
oncological terms, respectively, and only 926 manuscripts were
extracted by using both terms (Figure 1A), which indicates that
the outcomes of miRNA studies might not be efficiently shared
between the different disciplines. To bridge the gap between
miRNA studies in cardiology and oncology, representative cardio-
miRs upregulated in human heart failure were selected based
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FIGURE 1 | Cardio-miRNAs upregulated in human heart failure. (A)
Bibliology of miRNAs, cardio-miRs, and onco-miRs. (B) Flowchart of
representative cardio-miR selection. Based on exploratory screening of
miRNA expression reports (van Rooij et al., 2006; Matkovich et al., 2009;
Naga Prasad et al., 2009; Zhu et al., 2013) and validation process utilizing
next-generation sequence report (Leptidis et al., 2013), miR-24, miR-125b,
miR-195, and miR-214 were selected as representative cardio-miRs that
are upregulated in human heart failure. (C) Heat map of miRNA
expression profiles in human heart failure. Red, upregulated; green,
downregulated.
on database screening. The targets and functions of these miR-
NAs in cardiovascular diseases and cancers are comprehen-
sively reviewed, and then circulating miRNA-based diagnostics
for non-cancerous and cancerous diseases are discussed with a
focus on personal diversity related to genetic and environmental
factors.
REPRESENTATIVE CARDIO-miRs UPREGULATED IN HEART FAILURE
Heart failure is a progressive decline in cardiac functions that
occurs at the end stage of cardiovascular diseases, such as ischemic
heart disease, hypertension and diabetes (Hill and Olson, 2008;
Shah and Mann, 2011; Zhou et al., 2013b). Myocardial infarction
is caused by coronary artery occlusion, which leads to the death of
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cardiomyocytes in the infarcted region owing to insufficient oxy-
gen supply. Ischemic stress occurs in surviving cardiomyocytes
in the surrounding or peripheral area of an infarcted region,
and then hypertrophic growth of myocardiocytes and interstitial
fibrosis occur in the non-infarcted region of the heart. By con-
trast, persistent pressure overload causes cardiac wall thickening
of the left ventricle and hypertrophic growth of cardiomyocytes.
Cardiac hypertrophy leads to maladaptive remodeling of the left
ventricle and eventually results in patient death owing to fatal
arrhythmia and/or heart failure.
Forty-seven reports were recovered by initial screening of the
literature in the PubMed and Web of Science (WoS) databases
by using “heart failure,” “miRNA or miRNAs,” and “microar-
ray.” Then, four reports on microarray analyses (van Rooij et al.,
2006; Matkovich et al., 2009; Naga Prasad et al., 2009; Zhu et al.,
2013) were selected by critical reading (Figure 1B). Based on the
criterion “miRNA that is upregulated in at least two reports on
microarray analyses,” miR-24, miR-125b, miR-195, and miR-214
were selected as candidate representative cardio-miRs that are
upregulated in human heart failure (Figure 1C). Because data
obtained by using microarray analyses are not always correct,
upregulation of miR-24, miR-125b, miR-195, and miR-214 in
human heart failure were then validated by using a deep sequenc-
ing report on miRNA profiles in human heart failure (Leptidis
et al., 2013). Based on the exploration and validation processes,
miR-24, miR-125b, miR-195, and miR-214 were designated the
representative cardio-miRs upregulated in human heart failure
(Figure 1B).
miR-24
Human chromosomal loci of miR-24 genes
miR-24 is derived from the miR-23b/miR-27b/miR24-1
locus at human chromosome 9q22.32 and the miR-23a/
miR-27a/miR-24-2 locus at human chromosome 19p13.13
(Figure 2).
Targets of miR-24
miRNA targets demonstrated in rodents are not always conserved
in humans owing to species divergence (Le et al., 2009), while
putative miRNA targets predicted by using bioinformatics tools,
such as TargetScan (http://www.targetscan.org), PicTar (http://
pictar.mdc-berlin.de) and miRanda (http://www.microrna.org),
are not always true. In this review, miRNA targets validated in
human cells are listed up (Table 1).
ACVR1B (Activin receptor 1B) (Wang et al., 2008a),
ARHGAP19 (Amelio et al., 2012), AURKB (Aurora kinase B)
(Lal et al., 2009a), BCL2 (Srivastava et al., 2011), BCL2L11 (pro-
apoptotic BIM) (Qian et al., 2011), CCNA2 (Cyclin A2) (Lal et al.,
2009a), CDC2 (Lal et al., 2009a), CDK4 (Cyclin-dependent kinase
4) (Lal et al., 2009a), CDKN1B (p27 KIP1) (Giglio et al., 2013),
CDKN2A (p16 INK4a) (Lal et al., 2008), DHFR (Dihydrofolate
reductase) (Mishra et al., 2007), DIAPH1 (Diaphanos homolog 1)
(Zhou et al., 2013a), DUSP16 (MKP7) (Zaidi et al., 2009), E2F2
(Lal et al., 2009a), eNOS (NOS3) (Meloni et al., 2013), FAF1 (Fas-
associated factor 1) (Qin et al., 2010), FEN1 (Lal et al., 2009a),
FGFR3 (FGF receptor 3) (Rio-Machin et al., 2013), GATA2
(Fiedler et al., 2011), H2AFX (Histone H2AX) (Lal et al., 2009b),
HNF4A (HNF4α) (Takagi et al., 2010), JPH2 (Junctophilin 2)
(Xu et al., 2012b), LIMK2 (LIM-domain kinase 2) (Zhou et al.,
2013a),MEN1 (Luzi et al., 2012),MYC (c-Myc) (Lal et al., 2009a),
NET1 (NET1A or ARHGEF8) (Papadimitriou et al., 2012), PAK4
(Fiedler et al., 2011), PTPN9 (Protein tyrosine phosphatase, non-
receptor type 9) (Du et al., 2013), PTPRF (Protein tyrosine
phosphatase, receptor type F) (Du et al., 2013), RASA1 (Ras GAP)
(Fiedler et al., 2011), SH3PXD2A (TSK5) (Amelio et al., 2012),
SLC4A1 (Anion exchanger 1) (Wu et al., 2010), SPRY2 (Sprouty
FIGURE 2 | Human chromosomal loci ofmiR-24-1,miR-24-2,miR-125b-1,miR-125b-2,miR-195, andmiR-214.
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Table 1 | Validated targets of miR-24, miR-125b, miR-195, and
miR-214.
miR-24 miR-125b miR-195 miR-214
ACVR1B ARID3B ACVR2A ASF1B
ARHGAP19 BAK1 ARL2 BCL2L2
AURKB BCL2 BCL2 β-catenin
BCL2 BCL2L2 BCL2L2 BIM
BIM BMPR1B BIRC5 CADM1
CCNA2 CBFB (CBFβ) CCND1 CCL5
CDC2 CDH5 CCNE1 CD276 (B7-H3)
CDK4 CDKN2A (p14) CDC42 EZH2
CDKN1B (p27) DICER1 CDK4 FGFR1
CDKN2A (p16) E2F3 CDK6 GALNT7
DHFR EDN1 E2F3 HDGF
DIAPH1 EPO GLUT3 ING4
DUSP16 EPOR IKKα ITGA3
E2F2 ERBB2 MYB LTF
eNOS (NOS3) ERBB3 RAF1 LZTS1
FAF1 ETS1 TAB3 MAP2K3
FEN1 FGFR2 VAV2 MAPK8
FGFR3 IL6R VEGF NRAS
GATA2 IRF4 WEE1 PSMD10
H2AFX JUN (c-Jun) WNT7A PTEN
HNF4A LIN28A TFAP2C
JPH2 LIN28B TP53
LIMK2 MCL1 TWIST1
MEN1 MMP13 UBE2I
MYC (c-Myc) MUC1 XBP1
NET1 NCOR2
PAK4 PGF
PTPN9 PRDM1
PTPRF SIRT7
RASA1 Smoothened
SH3PXD2A ST18
SLC4A1 STARD13
SPRY2 STAT3
ST7L TET2
TRIB3 TNF (TNF-α)
XIAP TNFSF4
ZNF217 TP53
homolog 2) (Li et al., 2013a), ST7L (Chen et al., 2013a), TRIB3
(Tribbles pseudokinase 3) (Chan et al., 2010), XIAP (X-linked
inhibitor of apoptosis) (Xie et al., 2013), and ZNF217 (Zinc fin-
ger protein 217) (Szczyrba et al., 2013) are all validated targets of
miR-24 (Table 1).
Involvement of miR-24 in cardiovascular diseases
miR-24 is upregulated in ischemic heart endothelial cells as a
result of hypoxia-induced HIF-dependent transcription, but it is
then transiently downregulated in adjacent surviving regions of
acute myocardial infarction owing to the recovery of blood sup-
ply (Fiedler et al., 2011; Qian et al., 2011; Camps et al., 2014).
miR-24 promotes cardiomyocyte survival through repression of
pro-apoptotic Bim (Qian et al., 2011) and reduces cardiac fibrosis
through repression of Furin protease that controls the activa-
tion of latent TGFβ (Wang et al., 2012b). On the other hand,
miR-24 inhibits the survival, migration, proliferation and tube
formation of endothelial cells (angiogenesis) through repression
of eNOS and actin cytoskeleton regulators, such as DIAPH1,
LIMK2, and PAK4 (Fiedler et al., 2011; Meloni et al., 2013; Zhou
et al., 2013a). miR-24 is upregulated in the chronic phase after
myocardial infarction and promotes hypertrophic growth of car-
diomyocytes in mouse model experiments and disturbs cardiac
contraction through repression of JPH2 that is involved in the
excitation-contraction coupling process of the heart (van Rooij
et al., 2006; Xu et al., 2012b). Because miR-24 protects car-
diomyocytes themselves and reduces cardiac fibrosis but inhibits
angiogenesis and deteriorates heart failure, miR-24 is a multi-
functional cardio-miR that plays good and bad roles in heart
failure (Figure 3A).
Involvement of miR-24 in cancers
miR-24 is transcriptionally upregulated in acute myeloid
leukemia (AML) with t(8;21) by the RUNX1-RUNX1T1 (AML1-
ETO) fusion protein, which promotes proliferation and blocks
differentiation of myeloid cells through repression of DUSP16
and subsequent activation of mitogen-activated protein kinase
(MAKP) signaling (Zaidi et al., 2009). miR-24 is transcription-
ally upregulated in breast cancer with lymph node metastasis in
part by MYC (Li et al., 2013a), and overexpression of miR-24
in MCF-7 breast cancer cells promotes invasion and metastasis
through repression of SPRY2 and subsequent MAPK activation
(Li et al., 2013a). miR-24 is upregulated by the E6 and E7 onco-
proteins of human papilloma virus type 16 (HPV16), which
promotes proliferation through p27 repression (McKenna et al.,
2014). Upregulation of miR-24 in glioblastoma promotes sur-
vival, proliferation and invasion through repression of tumor
suppressor ST7L (Chen et al., 2013a). Upregulation of miR-
24 in pancreatic endocrine tumors (Volinia et al., 2006) and
parathyroid tumors (Luzi et al., 2012) can contribute to the
progression of multiple endocrine neoplasia type 1 (MEN1)
syndrome through repression of its causative gene product.
miR-24 is also upregulated in colon cancer (Volinia et al.,
2006), lung adenocarcinoma (Yanaihara et al., 2006), pancre-
atic ductal adenocarcinoma (Jamieson et al., 2012) and gas-
tric cancer (Volinia et al., 2006; Bandres et al., 2009). Because
pro-tumor miR-24 promotes survival, proliferation and inva-
sion through repression of BIM, FAF1, p16, p27, SPRY2, and
ST7L (Figure 3A), oncogenic miR-24 is upregulated in human
cancers.
By contrast, miR-24 is downregulated in A549 and H1437
non-small-cell lung cancer cells owing to copy number loss of
the miR-24-2 locus (Xie et al., 2013) (Table 2). miR-24 is also
downregulated in prostate cancer (Volinia et al., 2006) and hep-
atocellular carcinoma (HCC) recurring after liver transplanta-
tion (Han et al., 2012). Because anti-tumor miR-24 promotes
differentiation, growth arrest and apoptosis through repression
of AURKB, BCL2, CCNA2, CDC2, CDK4, E2F2, MYC, and
XIAP (Figure 3A), tumor suppressor miR-24 is downregulated in
human cancers.
miR-24 functions as an oncogenic or tumor suppressor
miRNA in a cancer (sub)type- or cell line-dependent manner
(Figure 3A).
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FIGURE 3 | miRNA functions in cardiology and oncology. (A) miR-24. (B)
miR-125b. (C) miR-195. (D) miR-214. Targets for pro-tumor, anti-tumor,
pro-cardio and anti-cardio functions of each miRNA are shown. miR-125b is a
good cardio-miR that protects cardiomyocytes. miR-195 is a bad cardio-miR
that elicits cardiomyopathy and heart failure. miR-24 and miR-214 are
bi-functional cardio-miRs. By contrast, miR-24, miR-125b, miR-195, and
miR-214 function as oncogenic or tumor suppressor miRNAs in a cancer
(sub)type-dependent manner.
miR-125b
Human chromosomal loci of miR-125b genes
miR-125b is derived from the miR-125b-1 and miR-125b-2 loci.
miR-125b-1 is clustered with let-7a-2 and miR-100 at human
chromosome 11q24.1 andmiR-125b-2 is clustered with let-7c and
miR-99a at human chromosome 21q21.1 (Figure 2).
Targets of miR-125b
ARID3B (Akhavantabasi et al., 2012), BAK1 (BCL2-
antagonist/killer 1) (Shi et al., 2007), BCL2 (Zhao et al.,
2012a), BCL2L2 (anti-apoptotic BCL-W) (Gong et al., 2013),
BMPR1B (Sætrom et al., 2009), CBFB (Core binding factor β)
(Lin et al., 2011), CDH5 (VE-cadherin) (Muramatsu et al., 2013),
CDKN2A (p14 ARF) (Amir et al., 2013), DICER1 (Klusmann
et al., 2010), E2F3 (Huang et al., 2011a), EDN1 (Endothelin 1)
(Li et al., 2010), EPO (Ferracin et al., 2013), EPOR (Ferracin
et al., 2013), ERBB2 (Scott et al., 2007), ERBB3 (Scott et al.,
2007), ETS1 (Zhang et al., 2011), FGFR2 (Xu et al., 2011), IL6R
(Gong et al., 2013), IRF4 (Malumbres et al., 2009), JUN (c-Jun)
(Kappelmann et al., 2013), LIN28A (Lin-28) (Wu and Belasco,
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Table 2 | Genetic and epigenetic alterations ofmiR-24,miR-125b,miR-195, andmiR-214.
miRNA gene Chromosome locus Disease Genetic alteration Epigenetic alteration miRNA expression
miR-24-1 9q22.32
miR-24-2 19p13.13 Lung cancer Deletion Down
miR-125b-1 11q24.1 AML and MDS t(2;11)(p21;q24) Up
BCP-ALL t(11;14)(q24;q32) Up
Cervical cancer Deletion Down
Breast cancer Epigenetic silencing Down
miR-125b-2 21q21.1 DS-AMKL 21 trisomy Up
miR-195 17p13.1 Colorectal adenoma Deletion Epigenetic silencing Down
Colorectal cancer Deletion Down
Breast cancer Epigenetic silencing Down
Gastric cancer Epigenetic silencing Down
miR-214 1q24.3 Liposarcoma Gene amplification Up
Breast cancer Deletion Down
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; DS-AMKL, Down syndrome with acute
megakaryocytic leukemia.
2005), LIN28B (Liang et al., 2010), MCL1 (Gong et al., 2013),
MMP13 (Xu et al., 2012c), MUC1 (Rajabi et al., 2010), NCOR2
(Yang et al., 2012a), PGF (Placental growth factor) (Alpini et al.,
2011), PRDM1 (BLIMP1) (Malumbres et al., 2009), SIRT7 (Kim
et al., 2013a), Smoothened (SMO) (Ferretti et al., 2008), ST18
(Klusmann et al., 2010), STARD13 (Tang et al., 2012), STAT3
(Liu et al., 2011), TET2 (Cheng et al., 2013), TNF (TNF-α)
(Rajaram et al., 2011), TNFSF4 (Smirnov and Cheung, 2008),
and TP53 (Le et al., 2009) are representative targets of miR-25b
(Table 1).
Involvement of miR-125b in cardiovascular diseases
miR-125b and LIN28A are human homologs of Caenorhabditis
elegans (C. elegans) lin-4 and lin-28, respectively. C. elegans
lin-4 is involved in the repression of lin-28 to orchestrate mor-
phogenesis during larval stage, whereas human miR-125b is
involved in the repression of LIN28A during the differentia-
tion of embryonic stem cells (ESCs) into myocardial precur-
sors and cardiomyocytes (Wu and Belasco, 2005; Wong et al.,
2012).
miR-125b is physiologically expressed in perivascular stro-
mal cells rather than cardiomyocytes of the developing mouse
heart (Schneider et al., 2011) and in cardiac valves rather than
myocardium of the adult rat heart (Vacchi-Suzzi et al., 2013).
miR125b is upregulated in mouse cardiac endothelial cells dur-
ing endothelial-to-mesenchymal transition (EndMT) induced by
TGF-ß (Ghosh et al., 2012). In addition, mir-125b is upregulated
in early-stage cardiac hypertrophy after aortic banding (Busk
and Cirera, 2010) and also in late-stage cardiac hypertrophy and
heart failure (van Rooij et al., 2006). Ectopic miR-125b expres-
sion by using adenovirus vector does not elicit cardiomyocyte
hypertrophy in vitro (van Rooij et al., 2006), whereas ectopic miR-
125b expression by using lentivirus reduces myocardial infarct
size and preserves cardiac functions in a mouse experimen-
tal model of acute myocardial infarction (Wang et al., 2014b).
miR-125b is a good cardio-miR that protects the heart from
ischemia/reperfusion injury (Figure 3B).
Involvement of miR-125b in human cancers
miR-125b is overexpressed in hematological malignancies owing
to genetic alterations, such as chromosomal translocation and
copy number gain (Table 2). miR-125b-1 at human chromo-
some 11q24.1 is upregulated as a result of chromosomal translo-
cation in AML and myelodysplastic syndrome (MDS) with
t(2;11)(p21;q24) (Bousquet et al., 2008; Thorsen et al., 2012) and
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with
t(11;14)(q24;q32) (Chapiro et al., 2010). miR-125b-2 at human
chromosome 21q21.1 is upregulated as a result of copy number
gain (21 trisomy) in Down syndrome with acute megakary-
ocytic leukemia (DS-AMKL) (Klusmann et al., 2010), which leads
to the proliferation and self-renewal of hematopoietic progeni-
tors of megakaryocytic and erythroid lineages in part through
repression of DICER1 and ST18. miR-125b is also upregulated
in childhood ALL with t(12;21)(p13.1;q22) (ETV6/RUNX1-ALL)
(Gefen et al., 2010), pancreatic endocrine tumors (Volinia et al.,
2006) and urothelial cancer at T2/T3 stages (Veerla et al., 2009).
Upregulation of pro-tumor (oncogenic) miR-125b in human
cancers promotes proliferation, survival and drug resistance of
tumor cells through repression of BAK1, p14, ST18, and TP53
(Figure 3B).
miR-125b is repressed in solid tumors as a result of dele-
tion and epigenetic silencing (Table 2). miR-125b is downreg-
ulated in in cervical cancer owing to a deletion of chromo-
some 11q24.1 that involves miR-125b-1 (Wilting et al., 2013)
and in oral squamous cell carcinoma (OSCC) owing to dele-
tions of chromosome 11q or 21 involving miR-125b-1 or miR-
125b-2, respectively (Henson et al., 2009). miR-125b is down-
regulated in breast cancer (Zhang et al., 2011) and HCC
(Alpini et al., 2011) owing to epigenetic silencing induced by
CpG hypermetheylation of promoter region(s). miR-125b is
also downregulated in prostate cancer (Porkka et al., 2007;
Ozen et al., 2008) and colorectal cancer (Chen et al., 2009).
Downregulation of anti-tumor (tumor suppressor) miR-125b
in human cancers promotes survival, proliferation and inva-
sion of tumor cells through de-repression of BCL2, BCL2L2,
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E2F3, ERBB2, FGFR2, MCL1, SIRT7, Smoothened and STAT3
(Figure 3B).
miR-125b also functions as an oncogenic or tumor suppressor
miRNA in a context-dependent manner (Figure 3B).
miR-195
Human chromosomal locus of miR-195 gene
miR-195 is derived from the miR-497/miR-195 locus at human
chromosome 17p13.1 (Figure 2).
Targets of miR-195
ACVR2A (Bai et al., 2012), ARL2 (ADP-ribosylation factor-like
2) (Zhou et al., 2013c), BCL2 (Liu et al., 2010), BCL2L2 (Yang
et al., 2012b), BIRC5 (API4, Apoptosis inhibitor 4) (Itesako et al.,
2014), CCND1 (Cyclin D1) (Xu et al., 2009), CCNE1 (Cyclin
E1) (Hui et al., 2013), CDC42 (Wang et al., 2013c), CDK4
(Lin et al., 2012b), CDK6 (Xu et al., 2009), E2F3 (Xu et al.,
2009), GLUT3 (SLC2A3) (Fei et al., 2012), IKKα (CHUK) (Ding
et al., 2013), MYB (Zhou et al., 2014), RAF1 (Li et al., 2011),
TAB3 (TAK1/MAP3K7-binding protein 3) (Ding et al., 2013),
VAV2 (Wang et al., 2013c), VEGF (Wang et al., 2013c), WEE1
(Bhattacharya et al., 2013), and WNT7A (Itesako et al., 2014) are
all validated targets of miR-195 (Table 1).
Involvement of miR-195 in cardiovascular diseases
During early post-natal development of mice, miR-195 is upreg-
ulated in cardiac ventricles and induces cell-cycle arrest in car-
diomyocytes through repression of cell cycle regulators, such as
Cdc2a, Chek1, Birc5, Nusap1, and Spag5 (Porrello et al., 2011).
Overexpression of miR-195 in the developing heart of trans-
genic mice by using the β-myosin heavy chain (MHC) promoter
gives rise to perinatal cardiomyopathy in one line and ventric-
ular hypoplasia and ventricular septal defects in another line
(Porrello et al., 2011). Overexpression of miR-195 in primary
neonatal rat cardiomyocytes by using adenoviral vector leads
to hypertrophic growth and sarcomeric assembly, and overex-
pression of miR-195 in the heart of post-natal transgemic mice
by using the α-MHC promoter gives rise to cardiac hyper-
trophy and dilated cardiomyopathy (van Rooij et al., 2006).
In transgenic mice with the α-MHC mutation R403Q, miR-
195 upregulation and subsequent repression of Cab39 in the
heart leads to hypertrophic cardiomyopathy owing to inhibi-
tion of Lkb1/Strad/Cab39-dependent AMPK signaling (Chen
et al., 2012). Together these facts indicate that miR-195 is a
bad cardio-miR that elicits hypertrophic cardiomyopathy, dilated
cardiomyopathy and heart failure (Figure 3C).
Involvement of miR-195 in cancers
miR-195 is upregulated in metastatic melanoma (Bhattacharya
et al., 2013) and some cases of lung cancer (Volinia et al., 2006),
colorectal cancer (Ding et al., 2013), prostate cancer (Volinia et al.,
2006), gastric cancer (Bandres et al., 2009; Ding et al., 2013) and
HCC (Ding et al., 2013). miR-195 can function as an oncogenic
miRNA through repression of WEE1 kinase (Figure 3C).
By contrast, miR-195 is preferentially downregulated in breast
cancer (Li et al., 2011), gastric cancer (Deng et al., 2013; Ding
et al., 2013), colorectal cancer (Chen et al., 2009; Liu et al., 2010;
Guo et al., 2013), HCC (Xu et al., 2009; Wang et al., 2013c), blad-
der cancer (Lin et al., 2012b; Itesako et al., 2014) and prostate
cancer (Porkka et al., 2007).miR-195 is repressed in breast cancer
(Li et al., 2011) and gastric cancer (Deng et al., 2013) owing to
hypermethylation of CpG islands upstream of the miR-497/miR-
195 locus. miR-195 is repressed in colorectal cancer owing to
deletion of the miR-497/miR-195 locus (Guo et al., 2013), while
miR-195 is repressed in colorectal adenoma mainly owing to epi-
genetic silencing and in part owing to deletion (Menigatti et al.,
2013). miR-195 is downregulated in human cancers and pre-
cancerous lesions as a result of epigenetic silencing and deletion
(Table 2). Because miR-195 is involved in repression of cell cycle
accelerators (CCND1, CCNE1, CDK4, CDK6, and E2F3) and
anti-apoptotic factors (BCL2, BCL2L2, and BIRC5) (Figure 3C),
miR-195 functions as a tumor suppressor miRNA in various types
of human cancers.
miR-214
Human chromosomal locus of miR-214 gene
miR-214 is derived from themiR-199a-2/miR-214 locus at human
chromosome 1q24.3 (Figure 2).
Targets of miR-214
ASF1B (Misiewicz-Krzeminska et al., 2013), BCL2L2 (Wang et al.,
2013a), ß-catenin (CTNNB1) (Xia et al., 2012), BIM (Zhang et al.,
2014), CADM1 (IGSF4A) (Momose et al., 2013), CCL5 (C-C
motif ligand 5) (Mitra et al., 2012), CD276 (B7-H3) (Nygren
et al., 2014), EZH2 (Derfoul et al., 2011), FGFR1 (Wang et al.,
2013b), GALNT7 (N-acetylgalactosaminyltransferase 7) (Peng
et al., 2012), HDGF (MGG1L2) (Shih et al., 2012b), ING4 (Zhang
et al., 2010), ITGA3 (Integrin α3) (Penna et al., 2011), LTF
(Lactoferrin) (Liao et al., 2010), LZTS1 (Xu and Wang, 2014),
MAP2K3 (MEK3) (Yang et al., 2009), MAPK8 (JNK1) (Yang
et al., 2009), NRAS (Huang et al., 2014a), PSMD10 (Misiewicz-
Krzeminska et al., 2013), PTEN (Yang et al., 2008), TFAP2C
(AP2γ) (Penna et al., 2011), TP53 (Xu et al., 2012a), TWIST1
(Twist) (Li et al., 2012), UBE2I (UBC9) (Zhao et al., 2012b),
and XBP1 (Duan et al., 2012) are all validated targets of miR-214
(Table 1).
Involvement of miR-214 in cardiovascular diseases
miR-214 is upregulated as a result of cardiac ischemia and
heart failure. In a mouse model of ischemic cardiac injury
induced by permanent ligation of the left anterior descending
coronary artery, miR-214 prevents cardiomyocyte death owing
to Ca2+ overload, subsequent cardiac insufficiency and cardiac
fibrosis through repression of Slc8a1 (Ncx1, sodium/calcium
exchanger), which is the primary Ca2+ outflow pump in car-
diomyocytes (Aurora et al., 2012). miR-214 protects primary
neonatal rat cardiomyocytes from apoptosis induced by ischemia-
reperfusion injury and represses Bim, Camk2d (Calmodulin
kinase II delta) and Slc8a1 (Aurora et al., 2012). miR-214 also
protects primary neonatal rat cardiomyocytes from apoptosis
induced by H2O2 through PTEN repression (Lv et al., 2014).
Overexpression of miR-214 in transgenic mice under control of
the α-MHC promoter does not induce a deteriorating cardiac
phenotype; however, adenovirus-mediated pri-miR-214 delivery
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and lentivirus-mediated miR-214 delivery induce hypertrophic
growth of primary neonatal rat cardiomyocytes in part through
Ezh2 repression (van Rooij et al., 2006; Yang et al., 2013). miR-
214 is a bi-functional cardio-miR that plays good and bad roles
(Figure 3D).
Involvement of miR-214 in cancers
Copy number gain of the 1q24.3 region around themiR-214 locus
occurs in 35% of de-differentiated liposarcomas (Tap et al., 2011).
miR-214 is upregulated in ovarian cancer (Yang et al., 2008; Xu
et al., 2012a), gastric cancer (Volinia et al., 2006; Bandres et al.,
2009), pancreatic cancer (Zhang et al., 2010; Jamieson et al.,
2012), lung squamous cell carcinoma (Yanaihara et al., 2006),
Sézary syndrome (Narducci et al., 2011), liposarcoma (Tap et al.,
2011), osteosarcoma (Wang et al., 2014d) and nasopharyngeal
cancer (Zhang et al., 2014). miR-214 upregulation in primary
gastric cancer occurs as a result of its expression in mesenchy-
mal stem cells (MSCs) rather than cancer cells (Wang et al.,
2014a). Genetic alteration as well as tumor-stromal interaction
are involved in miR-214 upregulation in human cancers.
Copy number loss of the miR-214 locus occurs in 24% of
breast cancers (Derfoul et al., 2011). miR-214 is downregulated
in cervical cancer (Peng et al., 2012; Wang et al., 2013a), HCC
(Duan et al., 2012; Shih et al., 2012b), colorectal cancer (Chen
et al., 2009), breast cancer (Derfoul et al., 2011), cholangiocar-
cinoma (Li et al., 2012), glioma (Zhao et al., 2012b), prostate
cancer (Srivastava et al., 2013), and bladder cancer (Ratert et al.,
2013).
Malignant phenotypes of cancer cells, such as proliferation,
survival, drug resistance, invasion and metastasis, are induced
by miR-214 upregulation through repression of BIM, CADM1,
ING4, PTEN, TFAP2C, and TP53 and also by miR-214 down-
regulation through de-repression of BCL2L2, ß-catenin, EZH2,
FGFR1, GALNT7, HDGF, NRAS, TWIST1, UBE2I, and XBP1
(Figure 3D). miR-214 performs oncogenic functions in some
types/subtypes of human cancers and tumor-suppressor func-
tions in other types/subtypes of human cancers.
REGULATORY SIGNALING NETWORKS AND miRNA-BASED
THERAPEUTICS
Regulatory signaling networks are defined as mutual interactions
or cross-talks of receptor tyrosine kinase (RTK), G protein-
coupled receptor (GPCR) and other receptor signaling cascades
(Katoh, 2013a), which are involved in orchestration of fetal devel-
opment and post-natal homeostasis as well as pathogenesis of
non-cancerous and cancerous diseases. WNT, FGF Hedgehog,
Notch, TGF-ß, BMP, Nodal, and Activin signaling cascades are
major components of the regulatory signaling networks (Bailey
et al., 2007; Katoh, 2007; Jayasena et al., 2008; Boulter et al., 2012;
Nowell and Radtke, 2013; Coleman et al., 2014).
WNT signals are transduced through Frizzled receptors to
the ß-catenin-dependent (canonical) and ß-catenin-independent
(non-canonical) cascades (Cohen et al., 2007; Katoh and Katoh,
2007; Klaus and Birchmeier, 2008; Rao and Kühl, 2010). In the
absence of canonical WNT signaling, β-catenin is phosphorylated
by GSK-3β and is degraded in the proteasome system. By con-
trast, in the presence of canonical WNT signaling, β-catenin is
released from the APC/AXIN degradation complex and activates
transcription of canonical WNT target genes, such as CCND1,
FGF20, JAG1, and MYC (Figure 4A). ß-catenin is a direct target
of miR-200a (Saydam et al., 2009), miR-214 (Xia et al., 2012),
miR-320a (Sun et al., 2012), and miR-1826 (Hirata et al., 2012).
Downregulation of miR-200a, miR-214, miR-320a, andmiR-1826
de-repress ß-catenin and activate the canonical WNT signaling
cascade in human cancers.
FGF signals are transduced to the RAS-ERK, PI3K-AKT,
STAT3, and Ca2+-release signaling branches through FGFR1
(Figure 4B), FGFR2, FGFR3, and FGFR4 (Turner and Grose,
2010; Goetz and Mohammadi, 2013; Katoh and Nakagama,
2014). FGFR1 is a direct target of miR-16 (Chamorro-Jorganes
et al., 2011), miR-133b (Wen et al., 2013), miR-198 (Yang et al.,
2014), miR-214 (Wang et al., 2013b), miR-382 (Mor et al., 2013),
miR-424 (Chamorro-Jorganes et al., 2011), and miR-503 (Kim
et al., 2013b). Upregulation of miR-382 in olfactory neuroepithe-
lium of schizophrenia patients repress FGFR1 (Mor et al., 2013).
By contrast, downregulation of miR-133b and miR-214 in human
cancers (Wen et al., 2013; Wang et al., 2013b) and that of miR-424
and miR-503 in pulmonary artery epithelial cells of patients with
pulmonary arterial hypertension (Kim et al., 2013b) de-repress
FGFR1 and promote proliferation of tumor cells and endothelial
cells, respectively, through FGF signaling activation.
Hedgehog signals are transduced from Patched receptors to
Smoothened signal transducer, which activates GLI-dependent
transcription of target genes, such as BCL2, FOXC2, JAG2, and
MYCN (N-Myc) (Figure 4C). Hedgehog-Smoothened-GLI sig-
naling cascade is involved in the regulation of cellular survival,
proliferation, motility and stemness (Jiang and Hui, 2008; Katoh
and Katoh, 2009; Lin and Matsui, 2012a). Smoothened is a direct
target of miR-125b (Ferretti et al., 2008), miR-193b (González-
Gugel et al., 2013), miR-324-5p (Ferretti et al., 2008), miR-326
(Ferretti et al., 2008), and miR-338-3p (Huang et al., 2011b).
Downregulation of miR-125b, miR-193b, miR-324-5p, miR-326,
and miR-338-3p in human cancers de-repress Smoothened and
promotes tumor proliferation and invasion through aberrant
Hedgehog signaling activation.
miRNAs are therapeutic targets for non-cancerous diseases
as well as cancers, because disease-related miRNAs dysregu-
late the regulatory signaling networks (Katoh and Katoh, 2008;
Mo et al., 2013; Parpart and Wang, 2013; Katoh et al., 2013c).
Reduction of elevated pro-disease miRNA and restoration of
declined anti-disease miRNA are two major strategies of miRNA-
based therapeutics. Locked-nucleic-acid-modified anti-miRNA
oligonucleotides (LNA-antimiRs) are utilized for the reduction
of pro-disease miRNAs, while adenovirus and letivirus vectors
are utilized for the restoration of anti-disease miRNAs (Ji et al.,
2008; Kasinski and Slack, 2011; Shi et al., 2011; van Rooij and
Olson, 2012). Reduction of FGFR1-targeting miRNAs for cancer
therapy deteriorate diabetes and cardiac functions, because the
FGFR1-PI3K-AKT signaling cascade is involved in cancer pro-
motion (Katoh et al., 2013c) as well as diabetes control (Suh
et al., 2014). By contrast, restoration of miRNA targeting BAK1,
BIM, or PTEN for cardiomyocyte protection promotes survival
of tumor cells (Figure 3). miRNA-based therapy is at the risk of
adverse effects owing to repression of verified targets in different
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FIGURE 4 | WNT, FGF, and Hedgehog signaling cascades. (A) Canonical
WNT signaling cascade and β-catenin. Canonical WNT signaling activation
releases β-catenin from its degradation complex of APC and AXIN, which
results in nuclear translocation of β-catenin and transcriptional activation
of TCF/LEF-target genes, such as CCND1 (Cyclin D1), FGF20, JAG1, and
MYC (c-Myc). β-catenin is a direct target of miR-200a, miR-214,
miR-320a, and miR-1826. (B) FGF signaling cascades and FGFR1. FGF
signals induce dimerization and auto-phosphorylation of a receptor
tyrosine kinase FGFR1, which activates downstream RAS-ERK, PI3K-AKT,
STAT3, and Ca2+-release signaling cascades. FGFR1 is a direct target of
miR-16, miR-133b, miR-198, miR-214, miR-382, miR-424, and miR-503.
(C) Hedgehog signaling cascade and Smoothened. Hedgehog signals are
transduced from Patched receptor to Smoothened signal transducer,
which activates transcription of GLI-target genes, such as BCL2, FOXC2,
JAG2, and MYCN (N-Myc). Smoothened is a direct target of miR-125b,
miR-193b, miR-324-5p, miR-326, and miR-338-3p.
disciplines. In addition, because multiple miRNAs repress the
same target (Figure 4) and each miRNA represses multiple tar-
gets (Table 1), miRNA-based therapy is also at the risk of adverse
effects owing to repression of unidentified targets in individual
patients. There are many obstacles before clinical application of
miRNA-based therapeutics.
CIRCULATING miR-24, miR-125b, miR-195, AND miR-214
miRNAs function within the cell where they were produced as
well as in other cells that receive miRNAs secreted or released
from the cell of their origin (Valadi et al., 2007; Skog et al.,
2008). Extracellular miRNAs are detected in various types of
body fluids, such as blood, tears, saliva, urine, vitreous humor,
cerebro-spinal fluid, pleural fluid, peritoneal fluid, seminal fluid,
breast milk, and amniotic fluid (Mitchell et al., 2008; Weber et al.,
2010; Ragusa et al., 2013). Extracellular miRNAs are classified into
miRNAs in the blood (circulating miRNAs) and those in other
body fluids. Because circulatingmiRNAs within exosomes (Taylor
and Gercel-Taylor, 2008), microvesicles (Hunter et al., 2008) and
high-density lipoprotein (Vickers et al., 2011) or those conjugated
with AGO2 protein (Arroyo et al., 2011) are stable, circulating
miRNAs are going to be utilized as diagnostics and prognostic
biomarkers (Table 3).
Circulating miR-24 is elevated in patients with breast can-
cer (Wu et al., 2012b; Sochor et al., 2014), lung cancer (Le
et al., 2012), malignant peripheral nerve sheath tumor with
the NF1 mutation (Weng et al., 2013), multiple system atrophy
(Vallelunga et al., 2014), osteoporotic fracture (Seeliger et al.,
2014), Parkinson’s disease (Vallelunga et al., 2014), preeclamp-
tic pregnancy (Wu et al., 2012a), rheumatoid arthritis (Murata
et al., 2013) and type 1 diabetes (Nielsen et al., 2012). Wang et al.
reported elevated miR-24 in type 2 diabetes patients (Wang et al.,
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Table 3 | Circulating miR-24, miR-125b, miR-195, and miR-214 in
diseases.
Circulating miRNA Disease
miR-24 Up Breast cancer
Lung cancer
Malignant peripheral nerve
sheath tumor with NF1
mutation
Multiple system atrophy
Osteoporotic fracture
Parkinson’s disease
Preeclamptic pregnancy
Rheumatoid arthritis
Type 1 diabetes
Type 2 diabetes
miR-24 Down Type 2 diabetes
miR-125b Up Breast cancer
Non-alcoholic fatty liver
disease
Non-small-cell lung cancer
Osteoporotic fracture
Rheumatoid arthritis
miR-125b Down Acute myocardial infarction
Alzheimer’s disease
Atopic dermatitis
Chronic kidney disease
Melanoma
Morbidly obese
Psoriasis vulgaris
Type 2 Diabetes
miR-195 Up Acute myocardial infarction
Breast cancer
Colorectal adenoma
Prostate cancer
miR-195 Down Adrenocortical carcinoma
Hepatocellular carcinoma
Schizophrenia
Type 2 Diabetes
miR-214 Up Breast cancer
Malignant peripheral nerve
sheath tumor
Ovarian cancer
miR-214 Down Acute myocardial infarction
Angina pectoris
2014c), whereas Zampetaki et al. reported reducedmiR-24 in type
2 diabetes patients (Zampetaki et al., 2010).
Circulating miR-125b is elevated in patients with breast can-
cer (Wang et al., 2012a; Mar-Aguilar et al., 2013), non-alcoholic
fatty liver disease (Pirola et al., 2014), non-small-cell lung cancer
(Yuxia et al., 2012; Cui et al., 2013), osteoporotic fracture (Seeliger
et al., 2014) and rheumatoid arthritis (Duroux-Richard et al.,
2014), whereas circulating miR-125b is reduced in patients with
acute myocardial infarction (Huang et al., 2014b), Alzheimer’s
disease (Tan et al., 2014), atopic dermatitis (Koga et al., 2014),
chronic kidney disease (Chen et al., 2013b), melanoma (Alegre
et al., 2014), morbidly obese (Ortega et al., 2013), psoriasis vul-
garis (Koga et al., 2014), and type 2 diabetes (Ortega et al., 2014).
Circulating miR-195 is elevated in patients with acute myocar-
dial infarction (Long et al., 2012), breast cancer (Heneghan
et al., 2010), colorectal adenoma (Kanaan et al., 2013), and
prostate cancer (Mahn et al., 2011), whereas circulating miR-
195 is reduced in adrenocortical carcinoma (Chabre et al., 2013),
HCC (Qu et al., 2011), schizophrenia (Shi et al., 2012),and type 2
diabetes (Ortega et al., 2014).
Circulating miR-214 is elevated in patients with breast cancer
(Schwarzenbach et al., 2012), malignant peripheral nerve sheath
tumor (Weng et al., 2013) and ovarian cancer (Taylor and Gercel-
Taylor, 2008), whereas circulating miR-214 is reduced in patients
with acute myocardial infarction and angina pectoris (Lu et al.,
2013).
These facts clearly indicate that circulating miRNAs reported
as cancer biomarkers are also dysregulated in non-cancerous dis-
eases, and that miRNAs reported as biomarkers of non-cancerous
diseases are also dysregulated in cancers (Table 3).
miRNA REGULATION BY GENETIC AND ENVIRONMENTAL FACTORS
Genetic factors are associated with individual traits and disease
susceptibility (Lichtenstein et al., 2000; Zimmet et al., 2001; Milne
et al., 2009). Single nucleotide polymorphisms (SNPs) and copy
number variations (CNVs) are major germ-line variations. The
SNP rs1434536 is located in the miR-125b-binding site within
the 3′-untranslated region (UTR) of BMPR1B. The C and T alle-
les of the rs1434536 SNP are sensitive and resistant to BMPR1B
repression by miR-125b, respectively (Sætrom et al., 2009). The
homozygous T genotype of rs1434536 is associated with increased
risk of breast cancer (Sætrom et al., 2009) and decreased risk of
endometriosis (Chang et al., 2013). Copy number loss of the miR-
195 locus occurs in autism patients (Vaishnavi et al., 2013). Copy
number gain of the miR-125b-2 locus occurs in Down syndrome
patients as a result of trisomy 21, which leads to elevated cir-
culating miR-125b in pregnant women with a Down syndrome
fetus (Kotlabova et al., 2013) and causes acute megakaryocytic
leukemia in Down syndrome patients (Klusmann et al., 2010).
Genetic factors directly affect expression profiles and functions of
miRNAs (Figure 5, upper left).
Environmental factors are also associated with disease sus-
ceptibility (Lichtenstein et al., 2000; Zimmet et al., 2001). Life
style (food/beverage intake, tobacco smoking, air toxin, irradia-
tion, etc.) and chronic infection (papilloma virus, hepatitis virus,
Helicobater pylori, etc.) are environmental factors affecting indi-
viduals. Human miR-125b is downregulated in the bronchial
epithelium of current smokers compared with never smokers
(Schembri et al., 2009), and rat miR-125b is downregulated in
the lungs of rats that were exposed to environmental smoke for
28 days (Izzotti et al., 2009). The expression profile of miRNAs in
airway epithelial cells is altered by air toxins, such as diesel exhaust
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FIGURE 5 | Regulation of circulating miRNAs. Genetic factors, such as
single nucleotide polymorphism (SNP) and copy number variation (CNV), as
well as environmental factors, including life style (food/beverage intake,
tobacco smoking, air toxin, irradiation, etc.) and chronic infection (human
papilloma virus, hepatitis virus, Helicobacter pylori, etc.) are involved in the
regulation of expression profiles and functions of miRNAs (upper part).
EZH2 and TET2 are epigenetic regulators that are involved in inactivation
and activation of genes through repressive histone marking and CpG-island
de-methylation, respectively. miRNA expression is downregulated by
epigenetic silencing, while epigenetic regulators are repressed by multiple
miRNAs. miRNAs and epigenetics are in the relationship of mutual
regulation (lower part). Genetic and environmental factors regulate
circulation miRNA profiles directly as well as indirectly through genetic and
epigenetic alterations.
particles and formaldehyde (Jardim et al., 2009; Rager et al.,
2011), whereas that in breast cancer cells is altered by endocrine
disruptors, such as o,p’-dichlorodiphenyltrichloroethane (DDT),
bisphenol A (BPA), fenhexamid and fludioxonil (Tilghman et al.,
2012; Teng et al., 2013). The circulating miRNA landscape is
altered by total-body γ-irradiation (Jacob et al., 2013) and by
uptake of dietary polyphenols, such as quercetin, hesperidin,
naringenin, anthocyanin, catechin, proanthocyanin, caffeic acid,
ferulic acid and curcumin (Milenkovic et al., 2012), in model
animal experiments. miRNA expression profile is altered by
chronic infection with human papilloma virus, hepatitis virus
and Helicobacter pylori, which are involved in pathogenesis of
cervical cancer (Wang et al., 2008b), HCC (Ladeiro et al., 2008;
Arzumanyan et al., 2013), and gastric cancer (Zhang et al., 2008),
respectively. Environmental factors directly alter circulating or
tissue levels of miRNAs (Figure 5, upper right).
Genetic alterations, such as gene amplification, deletion,
translocation, point mutation or single nucleotide variation
(SNV), occur in tumor cells during multi-stage carcinogenesis
owing to mutual interactions of genetic and environmental fac-
tors (Lichtenstein et al., 2000; Katoh et al., 2013c; Katoh and
Nakagama, 2014). SNVs in diffuse large B-cell lymphomas that
disrupt the miR-125b-binding site within the 3′-UTR of TP53
are associated with better prognosis of patients owing to de-
repression of a tumor suppressor TP53 (Li et al., 2013b). Effects
of gene amplification, deletion and translocation on expression
profiles of miR-24, miR-125b, miR-195, and miR-214 have been
described above (Table 2). Genetic alterations play a key role for
the regulation of miRNA profiles in somatic cells (Figure 5, upper
middle).
Epigenetics is chromatin-based genomic regulations that are
involved in the modulation of expression landscapes of mRNAs
and miRNAs during fetal development, post-natal homeostasis
and pathogenesis of human diseases (Datta et al., 2008; Kulis
and Esteller, 2010; Ordovás and Smith, 2010; Baylin and Jones,
2011; Dawson and Kouzarides, 2012). EZH2 and TET2 are rep-
resentative epigenetic regulators that are repressed by miR-214
and miR-125b, respectively (Table 1). EZH2 is a human homolog
of Drosophiula Enhancer of zeste, which is a component of the
Polycomb repressive complex 2 (PRC2) and PRC2-like complex
(Sparmann and van Lohuizen, 2006). EZH2 is involved in epi-
genetic silencing of PRC target genes through trimethylation of
histone H3 lysine 27 (H3K27me3) and CpG hypermethylation
of promoters (Figure 5, lower part). Because EZH2 is a tar-
get of miR-25 (Esposito et al., 2012), miR-26a (Sander et al.,
2008), miR-30d (Esposito et al., 2012), miR-101 (Varambally
et al., 2008), and miR-214 (Derfoul et al., 2011), downregula-
tion of miR-25, miR-26a, miR-30d, miR-101, and miR-214 in
human cancers are associated with EZH2 upregulation andmalig-
nant phenotypes. TET2 is involved in promoter de-methylation
through enzymatic conversion of 5-methylcytosine (5mC) to
5-hydroxylmethyl-cytosine (5hmC) (Ito et al., 2010). Loss-of-
function TET2 mutations occur in patients with myeloprolifer-
ative neoplasms, MDS and AML (Shih et al., 2012a), while upreg-
ulation of TET2-targeting miRNAs, such as miR-7, miR-29b,
miR-29c, miR-101, and miR-125b, occur in AML patients with
wild-typeTET2 (Cheng et al., 2013). miRNAs targeting EZH2 and
TET2 alter epigenetic regulations of disease-associated genes. By
contrast, disease-associated miRNAs are epigenetically silenced
owing to promoter CpG hypermethylation in human diseases
(Table 2). Epigenetic alterations also play a key role for the reg-
ulation of miRNA profiles in somatic cells (Figure 5, lower part).
Genetic and environmental factors dynamically alter expres-
sion profiles of miRNAs in individuals and also indirectly alter
miRNA profiles through genetic and epigenetic alterations in
patients with non-cancerous diseases and cancers (Figure 5).
CIRCULATING miRNA-BASED DIAGNOSTICS
Circulating miR-195 is upregulated in colorectal adenoma
(Kanaan et al., 2013); however, miR-195 in colorectal adenoma
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FIGURE 6 | Circulating miRNA association study (CMAS).
Dysregulation of circulating miRNAs occur in a variety of human
disease. Circulating miRNA profiles in several thousands of cases each
for non-cancerous common diseases (blue box) and major cancers (red
box) should be investigated for the establishment of miRNA-based
diagnostic platform.
tissues is repressed owing to epigenetic silencing and deletion
(Menigatti et al., 2013). Circulating miR-125b, miR-195, and
miR-214 are upregulated in breast cancer patients (Table 2),
whereas these miRNAs in breast cancer tissues are downregulated
owing to epigenetic silencing or deletion (Table 2). These facts
clearly indicate that circulating miRNAs in cancer patients are not
always derived from tumor tissues.
Because circulating miRNA profiles are dynamically regu-
lated by genetic and environmental factors (Figure 5), circu-
lating miRNA profiles of cancer patients reflect co-existing
non-cancerous diseases or individual whole-body conditions.
Therefore, circulating miRNA association studies (CMASs)
within several thousands of cases each for common non-
cancerous diseases as well as major cancers (Figure 6) should
be carried out to establish a reliable and robust platform of
miRNA-based diagnostics.
CONCLUSION
Cardio-miRs and onco-miRs bear some similarities in func-
tions and circulation profiles. miRNAs modulate the regu-
latory signaling networks that are involved in orchestration
of embryogenesis and homeostasis as well as pathogenesis
of human diseases. Circulating miRNA profiles within sev-
eral thousands of cases each for non-cancerous and cancerous
diseases are necessary for the establishment of miRNA-based
diagnostics.
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